Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 52, 2022 - Issue 8: 50th year of the DMDG
316
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Use of selective substrates and inhibitors to rapidly characterise batches of cryopreserved primary human hepatocytes for assessment of active uptake liability in drug discovery and development

ORCID Icon, , &
Pages 868-877 | Received 28 Jul 2022, Accepted 10 Sep 2022, Published online: 20 Dec 2022
 

Abstract

  1. The use of hepatocytes to predict human hepatic metabolic clearance is the gold standard approach. However whilst enzymes are well characterised, knowledge gaps remain for transporters. Furthermore, methods to study specific transporter involvement are often complicated by overlapping substrate specificity. Selective substrates and inhibitors would aid investigations into clinically relevant pharmacokinetic effects. However, to date no consensus has been reached.

  2. This work defines selective hepatic uptake transporter substrates and inhibitors for the six main human hepatocyte transporters (OATP1B1, OATP1B3, OATP2B1, NTCP, OAT2 & OCT1), and demonstrates their use to rapidly characterise batches of human hepatocytes for uptake transporter activity. Hepatic uptake was determined across a range of substrate concentrations, allowing the definition of kinetic parameters and hence active and passive components. Systematic investigations identified a specific substrate and inhibitor for each transporter, with no overlap between the specificity of substrate and inhibitor for any given transporter.

  3. Early characterisation of compound interactions with uptake transporters will aid in early risk assessment and chemistry design. Hence, this work further highlights the feasibility of a refined methodology for rapid compound characterisation for the application of static and dynamic models, for early clinical risk assessment and guidance for the clinical development plan.

Acknowledgements

The authors would like to acknowledge Shelby Barnett for assisting with the assay set-up and Margarida Sancho for suggesting PrestoBlueTM as a cell recovery method. Syeda Shah is acknowledged for performing the bioanalysis, and Prabha Peramuhendige and Vishal Ranglani are acknowledged for their contribution to scientific discussions. The authors would also like to thank Phil Stanley for his advice and support with the statistical analyses.

Author contributions

Participated in research design: Golding, Light, Ménochet. Conducted experiments: Golding, Light. Performed data analysis: Golding, Light. Contributed to the writing of the manuscript: Golding, Light, Ménochet, Williamson.

Disclosure statement

The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.